Literature DB >> 18482846

High level expression of the light chain of botulinum neurotoxin serotype C1 and an efficient HPLC assay to monitor its proteolytic activity.

Richa Rawat1, S Ashraf Ahmed, Subramanyam Swaminathan.   

Abstract

Botulinum neurotoxins (serotypes BoNT/A-BoNT/G) induce botulism, a disease leading to flaccid paralysis. These serotypes are highly specific in their proteolytic cleavage of SNAP-25 (synaptosomal-associated protein of 25kDa), VAMP (vesicle associated membrane protein) or syntaxin. The catalytic domain (light chain, LC) of the neurotoxin has a Zn(2+) dependent endopeptidase activity. In order to design drugs and inhibitors against these toxins, high level overexpression and characterization of LC of BoNTs along with the development of assays to monitor their proteolytic activity becomes important. Using the auto-induction method, we attained a high level expression of BoNT/C1(1-430) yielding more than 30mg protein per 500ml culture. We also developed an efficient assay to measure the activity of serotype C1 based on a HPLC method. SNAP-25 with varying peptide length has been reported in literature as substrates for BoNT/C1 proteolysis signifying the importance of remote exosites in BoNT/C1 required for activity. Here, we show that a 17-mer peptide corresponding to residues 187-203 of SNAP-25, which has earlier been shown to be a substrate for BoNT/A, can be used as a substrate for quantifying the activity of BoNT/C1(1-430). There was no pH dependence for the proteolysis, however the presence of dithiothreitol is essential for the reaction. Although the 17-mer substrate bound 110-fold less tightly to BoNT/C1(1-430) than SNAP-25, the optimal assay conditions facilitated an increase in the catalytic efficiency of the enzyme by about 5-fold.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18482846     DOI: 10.1016/j.pep.2008.03.010

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  5 in total

1.  Expression and purification of recombinant TAT-BoNT/A(1-448) under denaturing and native conditions.

Authors:  Parvaneh Saffarian; Shahin Najar Peerayeh; Jafar Amani; Firooz Ebrahimi; Hamid Sedighianrad; Raheleh Halabian; Abbas Ali Imani Fooladi
Journal:  Bioengineered       Date:  2016-08-26       Impact factor: 3.269

2.  Enhanced detection of type C botulinum neurotoxin by the Endopep-MS assay through optimization of peptide substrates.

Authors:  Dongxia Wang; Joan Krilich; Jakub Baudys; John R Barr; Suzanne R Kalb
Journal:  Bioorg Med Chem       Date:  2015-04-10       Impact factor: 3.641

3.  The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site.

Authors:  Rahman M Mizanur; Verna Frasca; Subramanyam Swaminathan; Sina Bavari; Robert Webb; Leonard A Smith; S Ashraf Ahmed
Journal:  J Biol Chem       Date:  2013-06-18       Impact factor: 5.157

4.  Tyrosine phosphorylation of botulinum neurotoxin protease domains.

Authors:  Stephen Toth; Ernst E Brueggmann; George A Oyler; Leonard A Smith; Harry B Hines; S Ashraf Ahmed
Journal:  Front Pharmacol       Date:  2012-06-04       Impact factor: 5.810

5.  Substrate binding mode and its implication on drug design for botulinum neurotoxin A.

Authors:  Desigan Kumaran; Richa Rawat; S Ashraf Ahmed; Subramanyam Swaminathan
Journal:  PLoS Pathog       Date:  2008-09-26       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.